These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34098559)

  • 1. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA; Rosenbaum DP; Yan A; Chertow GM
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
    Nakayama M; Kobayashi S; Kusakabe M; Ohara M; Nakanishi K; Akizawa T; Fukagawa M
    Clin Exp Nephrol; 2024 Feb; 28(2):153-164. PubMed ID: 37910313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.
    Yu S; Sun J; Guo X
    Ren Fail; 2024 Dec; 46(2):2410389. PubMed ID: 39351794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Luo H; Feng J; Zhang Y; Wang J; Xue G; Huang X; You S; Dong H; Li L; Li J; Xiao H; Ai X; Li X; Huang B
    Ther Apher Dial; 2023 Oct; 27(5):839-847. PubMed ID: 37349983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
    Block GA; Rosenbaum DP; Yan A; Greasley PJ; Chertow GM; Wolf M
    Nephrol Dial Transplant; 2019 Feb; 34(2):339-346. PubMed ID: 29617976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.
    Nitta K; Itoyama S; Ikejiri K; Kinoshita J; Nakanishi K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2023 Nov; 8(11):2243-2253. PubMed ID: 38025211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.
    Akizawa T; Sato Y; Ikejiri K; Kanda H; Fukagawa M
    Kidney Int Rep; 2021 Sep; 6(9):2371-2380. PubMed ID: 34514198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.
    Koiwa F; Sato Y; Ohara M; Nakanishi K; Fukagawa M; Akizawa T
    Sci Rep; 2023 Nov; 13(1):19100. PubMed ID: 37925471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.
    Inaba M; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Kidney Int Rep; 2022 Feb; 7(2):177-188. PubMed ID: 35155857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
    Block GA; Bleyer AJ; Silva AL; Weiner DE; Lynn RI; Yang Y; Rosenbaum DP; Chertow GM
    Kidney360; 2021 Oct; 2(10):1600-1610. PubMed ID: 35372979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
    Hertel J; Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Nephron; 2015; 130(4):229-38. PubMed ID: 26184491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Stefansson BV; Rydén-Bergsten T; Greasley PJ; Johansson SA; Knutsson M; Carlsson BC
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1597-1605. PubMed ID: 27340281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
    Cheng SC; Young DO; Huang Y; Delmez JA; Coyne DW
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1131-8. PubMed ID: 18385391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L
    Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.